Video Latest - ecancer

ALL: Combining paediatric-type therapy with minimal residual disease

Dr Alessandro Rambaldi - Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy

5 Dec 2016

Pracinostat and azacitidine for elderly AML

Prof Guillermo Garcia-Manero - MD Anderson Cancer Center, Houston, USA

5 Dec 2016

ASH 2016: AML, CLL and leukaemogenesis latest

Dr Farhad Ravandi - MD Anderson Cancer Center, Houston, USA

5 Dec 2016

Ineligibility required for 'anti-trials': inclusion in studies regardless of fitness

Prof Guillermo Garcia-Manero - MD Anderson Cancer Center, Houston, USA

5 Dec 2016

Vosaroxin for relapsed AML: Updates from VALOR

Dr Farhad Ravandi - MD Anderson Cancer Center, Houston, USA

5 Dec 2016

Impact of next-generation sequencing on treatment choice for MDS

Dr Ana Alfonso Pierola - MD Anderson Cancer Center, Houston, USA

4 Dec 2016

Obinutuzumab extends PFS for follicular lymphoma in GALLIUM trial

Dr Andrew Davies - University of Southampton, Southampton, UK

4 Dec 2016

Ibrutinib in CLL: RESONATE and resistance

Dr Jennifer Woyach - The Ohio State University Medical Center, Columbus, USA

4 Dec 2016

Large granular lymphocyte proliferations in MDS

Dr Christa Roe - H. Lee Moffitt Cancer Center, Tampa, USA

4 Dec 2016

Durable remissions with the VcR-CVAD regimen for MCL regardless of age

Dr Julie Chang - University of Wisconsin Hospital and Clinics, Madison, USA

4 Dec 2016

Tailoring therapy for leukaemia patients

Dr Mikkael Sekeres - Cleveland Clinic, Cleveland, USA

3 Dec 2016

Dose reduction of TKIs for CML patients with deep molecular response

Prof Mhairi Copland - University of Glasgow, Glasgow, UK

3 Dec 2016

Video